• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

确定 COVID-19 后期疾病为可能的长新冠和/或疫苗接种后果。

Determination of COVID-19 Late Disorders as Possible Long-COVID and/or Vaccination Consequences.

机构信息

Clinical Research Department, Pasteur Institute of Iran, Tehran, Iran.

Iranian Society for Support of Patients With Infectious Disease, Tehran, Iran.

出版信息

J Prim Care Community Health. 2024 Jan-Dec;15:21501319241251941. doi: 10.1177/21501319241251941.

DOI:10.1177/21501319241251941
PMID:38708693
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11075438/
Abstract

In this era in which the vast majority of the global population have developed COVID-19 infection and/or got vaccinated against it, identification of the late disorders as the vaccines' side effect or long-COVID manifestation seems essential. This study included the vaccinated individuals of 4 different vaccine regimens including inactivated virus-based, subunit protein, and adenovirus-based vaccines in a follow-up schedule 6-month post the booster shot. All the documented vaccine adverse events were thoroughly assessed considering the cases' medical history by Adverse Events Committee of Pasteur Institute of Iran. Totally 329 individuals who got 3 doses of vaccination were followed 6 months after the booster shots among whom 41 (12.4%) cases with the mean age of 40.9 ± 10.48 years had a type of disorder. Gynecological and osteoarticular involvements were the most common recorded disorders of which 73.1% were possibly linked to vaccination outcomes and the rest were affected by both long-COVID-19 and vaccination. Notably, the average time of symptoms persistence was 155 ± 10.4 days. This study has the advantage of long-term follow-up which presents various forms of late events in each episode of COVID-19 infection and vaccination. About 26.8% of people with persistent complications suffered from both long-COVOD/ vaccination in whom the differentiation between the vaccine side effect and long-COVID manifestation was quite challenging. Long-term follow-up studies in large population seems essential to outline the role of long-COVID and vaccination regarding persistent complications.

摘要

在这个全球绝大多数人都感染了 COVID-19 或接种了疫苗的时代,识别这些晚期疾病是疫苗的副作用还是长新冠的表现似乎至关重要。本研究纳入了 4 种不同疫苗方案的接种者,包括灭活病毒疫苗、亚单位蛋白疫苗和腺病毒疫苗,在加强针接种后进行了 6 个月的随访。伊朗巴斯德研究所的不良事件委员会对所有有记录的疫苗不良事件进行了彻底评估,同时考虑了病例的病史。在加强针接种后 6 个月,共有 329 名接种了 3 剂疫苗的人接受了随访,其中 41 例(12.4%)年龄为 40.9±10.48 岁的患者出现了某种类型的疾病。妇科和骨关节炎受累是最常见的记录疾病,其中 73.1%可能与疫苗结果有关,其余则受长新冠和疫苗的双重影响。值得注意的是,症状持续时间的平均时间为 155±10.4 天。本研究的优势在于长期随访,可以在每一次 COVID-19 感染和疫苗接种中呈现出各种形式的晚期事件。约 26.8%的持续性并发症患者同时患有长新冠/疫苗接种,区分疫苗副作用和长新冠表现具有挑战性。在大人群中进行长期随访研究对于阐明长新冠和疫苗接种在持续性并发症中的作用至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1679/11075438/d86bc50f8951/10.1177_21501319241251941-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1679/11075438/d86bc50f8951/10.1177_21501319241251941-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1679/11075438/d86bc50f8951/10.1177_21501319241251941-fig1.jpg

相似文献

1
Determination of COVID-19 Late Disorders as Possible Long-COVID and/or Vaccination Consequences.确定 COVID-19 后期疾病为可能的长新冠和/或疫苗接种后果。
J Prim Care Community Health. 2024 Jan-Dec;15:21501319241251941. doi: 10.1177/21501319241251941.
2
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗(灭活,Vero 细胞)有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验:一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
3
Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.一种雾化型腺病毒 5 型载体新冠疫苗(Ad5-nCoV)在成年人中的安全性、耐受性和免疫原性:一项开放标签、随机 1 期临床试验的初步报告。
Lancet Infect Dis. 2021 Dec;21(12):1654-1664. doi: 10.1016/S1473-3099(21)00396-0. Epub 2021 Jul 26.
4
Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.科里纳平(COReNAPCIN)作为一种 SARS-CoV-2 mRNA 疫苗,在健康伊朗成年人中作为第四种异源加强针的安全性和免疫原性:一项双盲、随机、安慰剂对照、为期 6 个月随访的 1 期临床试验。
Int Immunopharmacol. 2024 Jun 15;134:112192. doi: 10.1016/j.intimp.2024.112192. Epub 2024 May 17.
5
A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.不同新冠病毒疫苗接种后疾病情况的综述:伊朗病例报告的系统评价
Eur J Med Res. 2023 Nov 26;28(1):542. doi: 10.1186/s40001-023-01531-7.
6
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.针对 COVID-19 的一种改良信使核糖核酸-脂质纳米颗粒候选疫苗的安全性和免疫原性:一项 1 期、剂量递增研究的结果。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2408863. doi: 10.1080/21645515.2024.2408863. Epub 2024 Oct 18.
7
Monitoring and active surveillance of adverse events following the booster dose of AZD1222 vaccine in people vaccinated with Sinopharm BBIBP-CorV: a cohort study.国药集团BBIBP-CorV疫苗接种者接种AZD1222疫苗加强针后不良事件的监测与主动监测:一项队列研究
BMC Public Health. 2025 Feb 17;25(1):650. doi: 10.1186/s12889-025-21805-5.
8
Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study.评估 COVID-19 不同疫苗方案在 18 个月随访研究中的长期不良事件。
Pathog Dis. 2023 Jan 17;81. doi: 10.1093/femspd/ftad010.
9
Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.《ChAdOx1-nCoV-19 冠状病毒疫苗的长期安全性分析:印度北部优先接种人群的前瞻性观察研究结果》。
Drug Saf. 2023 Jun;46(6):553-563. doi: 10.1007/s40264-023-01301-8. Epub 2023 May 3.
10
Report on adverse events of COVID-19 vaccines in Iran: a comprehensive national prospective longitudinal analysis.伊朗新冠疫苗不良事件报告:一项全面的全国前瞻性纵向分析
Front Immunol. 2025 Feb 14;16:1504973. doi: 10.3389/fimmu.2025.1504973. eCollection 2025.

引用本文的文献

1
Late-Induced Autoimmune Disorders Post-COVID-19 Vaccination/Infection: Case Report From Iran.新冠疫苗接种/感染后迟发性自身免疫性疾病:来自伊朗的病例报告
Case Rep Med. 2025 Aug 28;2025:8815875. doi: 10.1155/carm/8815875. eCollection 2025.
2
Persistent CD19 B cell lymphopenia in critically ill COVID-19 patients 50 days after symptom onset.重症 COVID-19 患者症状出现 50 天后持续性 CD19 B 细胞淋巴细胞减少。
Front Cell Infect Microbiol. 2024 Nov 22;14:1488607. doi: 10.3389/fcimb.2024.1488607. eCollection 2024.

本文引用的文献

1
Long-term rheumatoid manifestations as a consequence of COVID-19 and/or vaccination: A case report after a 2-year follow-up.COVID-19和/或疫苗接种导致的长期类风湿性表现:2年随访后的病例报告
Heliyon. 2024 Jan 18;10(3):e24982. doi: 10.1016/j.heliyon.2024.e24982. eCollection 2024 Feb 15.
2
A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports.不同新冠病毒疫苗接种后疾病情况的综述:伊朗病例报告的系统评价
Eur J Med Res. 2023 Nov 26;28(1):542. doi: 10.1186/s40001-023-01531-7.
3
Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals.
异源加强免疫 PastoCovac Plus 对 ChAdOx1-S 或 BBIBP-CorV 初免个体的 COVID-19 免疫原性和安全性。
PLoS Pathog. 2023 Nov 1;19(11):e1011744. doi: 10.1371/journal.ppat.1011744. eCollection 2023 Nov.
4
COVID-19 vaccine hesitancy: A Systematic review of cognitive determinants.新冠病毒疫苗犹豫:认知决定因素的系统评价
Health Promot Perspect. 2023 Apr 30;13(1):21-35. doi: 10.34172/hpp.2023.03. eCollection 2023.
5
Assessment of long-term adverse events regarding different COVID-19 vaccine regimens within an 18-month follow-up study.评估 COVID-19 不同疫苗方案在 18 个月随访研究中的长期不良事件。
Pathog Dis. 2023 Jan 17;81. doi: 10.1093/femspd/ftad010.
6
PastoCovac and PastoCovac Plus as protein subunit COVID-19 vaccines led to great humoral immune responses in BBIP-CorV immunized individuals.巴斯德科瓦克和巴斯德科瓦克加作为蛋白质亚单位 COVID-19 疫苗,在 BBIP-CorV 免疫个体中引起了强烈的体液免疫反应。
Sci Rep. 2023 May 18;13(1):8065. doi: 10.1038/s41598-023-35147-y.
7
Identification and diagnosis of long COVID-19: A scoping review.长新冠的识别和诊断:范围综述。
Prog Biophys Mol Biol. 2023 Sep;182:1-7. doi: 10.1016/j.pbiomolbio.2023.04.008. Epub 2023 May 12.
8
Long-Term Safety Analysis of the ChAdOx1-nCoV-19 Corona Virus Vaccine: Results from a Prospective Observational Study in Priority Vaccinated Groups in North India.《ChAdOx1-nCoV-19 冠状病毒疫苗的长期安全性分析:印度北部优先接种人群的前瞻性观察研究结果》。
Drug Saf. 2023 Jun;46(6):553-563. doi: 10.1007/s40264-023-01301-8. Epub 2023 May 3.
9
A Case Report: Long Post-COVID Vaccination Syndrome During the Eleven Months After the Third Moderna Dose.病例报告:第三次接种莫德纳疫苗后11个月出现的长期新冠疫苗接种综合征
Cureus. 2022 Dec 12;14(12):e32433. doi: 10.7759/cureus.32433. eCollection 2022 Dec.
10
Long COVID: major findings, mechanisms and recommendations.长新冠:主要发现、机制和建议。
Nat Rev Microbiol. 2023 Mar;21(3):133-146. doi: 10.1038/s41579-022-00846-2. Epub 2023 Jan 13.